Literature DB >> 21939721

Population-based incidence of herpes zoster after introduction of a publicly funded varicella vaccination program.

Peter Tanuseputro1, Brandon Zagorski, Kevin J Chan, Jeffrey C Kwong.   

Abstract

BACKGROUND: Past varicella infection (chicken pox) may reactivate into herpes zoster (shingles). Varicella vaccination leads to a reduction in cases of varicella that may in turn increase herpes zoster rates due to reduction in the immune boosting effect of exposure to varicella zoster virus against varicella reactivation. We assessed the impact of childhood varicella vaccination in Ontario, Canada on zoster incidence and healthcare visits, and established baseline zoster rates prior to zoster vaccine introduction.
METHODS: We used population-based, administrative databases to identify zoster incidence and healthcare use from April 1992 to March 2010.
RESULTS: After routine varicella vaccination, zoster incidence rates decreased 29% for children aged 0-9 and changed minimally for other ages. Age-standardized rates of hospitalizations during the study period declined by 53%, while outpatient rates declined by 9%. The annual zoster incidence for those 60 or older was 740 per 100,000.
CONCLUSIONS: In the early post-varicella vaccination period, incidence rates of medically attended herpes zoster did not increase for the overall population and decreased moderately for children 9 years and younger, the age group targeted for varicella vaccination.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21939721     DOI: 10.1016/j.vaccine.2011.09.024

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  35 in total

Review 1.  Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective.

Authors:  Robert W Johnson; Marie-José Alvarez-Pasquin; Marc Bijl; Elisabetta Franco; Jacques Gaillat; João G Clara; Marc Labetoulle; Jean-Pierre Michel; Luigi Naldi; Luis S Sanmarti; Thomas Weinke
Journal:  Ther Adv Vaccines       Date:  2015-07

2.  Increasing Incidence of Herpes Zoster Over a 60-year Period From a Population-based Study.

Authors:  Kosuke Kawai; Barbara P Yawn; Peter Wollan; Rafael Harpaz
Journal:  Clin Infect Dis       Date:  2016-05-08       Impact factor: 9.079

Review 3.  Successes and challenges in varicella vaccine.

Authors:  Orestis Papaloukas; Georgia Giannouli; Vassiliki Papaevangelou
Journal:  Ther Adv Vaccines       Date:  2014-03

Review 4.  Cost-effectiveness of vaccination against herpes zoster.

Authors:  Pieter T de Boer; Jan C Wilschut; Maarten J Postma
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

5.  Effectiveness and cost-effectiveness of vaccination against herpes zoster in Canada: a modelling study.

Authors:  Mélanie Drolet; Zhou Zhou; Chantal Sauvageau; Philippe DeWals; Vladimir Gilca; Rachid Amini; Élodie Bénard; Marc Brisson
Journal:  CMAJ       Date:  2019-08-26       Impact factor: 8.262

6.  Varicella and herpes zoster hospitalizations before and after implementation of one-dose varicella vaccination in Australia: an ecological study.

Authors:  Anita E Heywood; Han Wang; Kristine K Macartney; Peter McIntyre
Journal:  Bull World Health Organ       Date:  2014-06-13       Impact factor: 9.408

7.  Secular trends of chickenpox among military population in Israel in relation to introduction of varicella zoster vaccine 1979-2010.

Authors:  Daniel Mimouni; Hagai Levine; Anat Tzurel Ferber; Inbal Rajuan-Galor; Michael Huerta-Hartal
Journal:  Hum Vaccin Immunother       Date:  2013-02-14       Impact factor: 3.452

8.  Examination of links between herpes zoster incidence and childhood varicella vaccination.

Authors:  Craig M Hales; Rafael Harpaz; M Riduan Joesoef; Stephanie R Bialek
Journal:  Ann Intern Med       Date:  2013-12-03       Impact factor: 25.391

9.  Epstein-Barr and other herpesvirus infections in patients with early onset type 1 diabetes treated with daclizumab and mycophenolate mofetil.

Authors:  Brett J Loechelt; David Boulware; Michael Green; Lindsey R Baden; Peter Gottlieb; Heidi Krause-Steinrauf; Adriana Weinberg
Journal:  Clin Infect Dis       Date:  2012-10-05       Impact factor: 9.079

10.  Influence of frequent infectious exposures on general and varicella-zoster virus-specific immune responses in pediatricians.

Authors:  Benson Ogunjimi; Evelien Smits; Steven Heynderickx; Johan Van den Bergh; Joke Bilcke; Hilde Jansens; Ronald Malfait; Jose Ramet; Holden T Maecker; Nathalie Cools; Philippe Beutels; Pierre Van Damme
Journal:  Clin Vaccine Immunol       Date:  2014-01-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.